Expert Video - What are mutation-driven MDS treatments?
MDS expert Rafael Bejar, MD, PhD, explains how mutation-driven treatments for myelodysplastic syndromes (MDS) target changes on specific genes such as IDH1 or IDH2. Other examples include the use of lenalidomide, chromosome deletions in 5q as potential drivers for treatment, and treatments targeted to mutations in the gene FLT3 are present.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.
This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
This activity is supported by an educational grant from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.